Showing 1 - 10 results of 10 for search '"Sanofi"' Skip to content

0 items (Full)

Advanced Search History Search by Map: Arctic Antarctic

Reset Filters

Content Provider: Directory of Open Access Journals: DOAJ Articles

Reset Filters

Show filters (1)

Content Provider: Directory of Open Access Journals: DOAJ Articles

Search Results - Open Polar - "Sanofi"

Search Results

Showing 1 - 10 results of 10 for search '"Sanofi"', query time: 0.22s Refine Results

Sort

List Grid Visual

Select Page | with selected:

Select result number 1
1

Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience

by Sebbag Robert, Kiechel Jean-René, Bompart François, Pecoul Bernard
Published in Malaria Journal (2011)
“... treatment recommendations and international regulatory agencies approval standards. In 2002, Sanofi-aventis...”

Get access
Get access

Article in Journal/Newspaper
Select result number 2
2

Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes.

by Rachel Bellone, Laurence Mousson, Chloé Bohers, Nathalie Mantel, Anna-Bella Failloux
Published in PLOS Neglected Tropical Diseases (2022)
“... embryonated eggs, led Sanofi to move towards alternative methods based on a state-of-the-art process using...”

Get access
Get access

Article in Journal/Newspaper
Select result number 3
3

The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.

by Maíra Aguiar, Nico Stollenwerk, Scott B Halstead
Published in PLOS Neglected Tropical Diseases (2016)
“... intensive care. A vaccine now licensed in several countries and developed by Sanofi Pasteur (CYD-TDV, named...”

Get access
Get access

Article in Journal/Newspaper
Select result number 4
4

Estudio de bioequivalencia de montelukast en tabletas masticables de 5 mg

by Ángela Piedad Medina, Francisco Javier Olaya, Mónica Patricia Navas, Ángela María Tilano, Enrique Muñoz
Published in Biomédica (2012)
“... de 5mg fabricadas por Sanofi-Aventis con la de Singulair®, montelukast en tabletas masticables de 5...”

Get access
Get access

Article in Journal/Newspaper
Select result number 5
5

The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response.

by Jacky Flipse, Jolanda M Smit
Published in PLOS Neglected Tropical Diseases (2015)
“... of Sanofi Pasteur. This vaccine has recently cleared Phase III, and efficacy results have been published...”

Get access
Get access

Article in Journal/Newspaper
Select result number 6
6

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.

by Francesco Checchi, Patrice Piola, Harriet Ayikoru, Florence Thomas, Dominique Legros, Gerardo Priotto
Published in PLoS Neglected Tropical Diseases (2007)
“... conditions.Eligible sequential late-stage patients received 400 mg/Kg/day eflornithine (Ornidyl, Sanofi-Aventis...”

Get access
Get access

Article in Journal/Newspaper
Select result number 7
7

Barriers to typhoid fever vaccine access in endemic countries

by Khan MI, Franco-Paredes C, Sahastrabuddhe S, Ochiai RL, Mogasale V, BD Gessner
Published 2017
“... Hospital, Albany, GA, USA; 4International Vaccine Institute, Seoul, Republic of Korea; 5Sanofi Pasteur...”

Get access

Article in Journal/Newspaper
Select result number 8
8

Projected Impact of Dengue Vaccination in Yucatán, Mexico.

by Thomas J Hladish, Carl A B Pearson, Dennis L Chao, Diana Patricia Rojas, Gabriel L Recchia, Héctor Gómez-Dantés, M Elizabeth Halloran, Juliet R C Pulliam, Ira M Longini
Published in PLOS Neglected Tropical Diseases (2016)
“... year period. Vaccine efficacy is based on phase III trial results for the Sanofi-Pasteur vaccine...”

Get access
Get access

Article in Journal/Newspaper
Select result number 9
9

Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.

by Pedro L Moro, Emily Jane Woo, Wendy Paul, Paige Lewis, Brett W Petersen, Maria Cano
Published in PLOS Neglected Tropical Diseases (2016)
“...BACKGROUND:In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed...”

Get access
Get access

Article in Journal/Newspaper
Select result number 10
10

Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement.

by Chen-Yi Chiang, Chien-Hsiung Pan, Chun-Hsiang Hsieh, Jy-Ping Tsai, Mei-Yu Chen, Hsueh-Hung Liu, Shih-Jen Liu, Pele Chong, Chih-Hsiang Leng, Hsin-Wei Chen
Published in PLoS Neglected Tropical Diseases (2013)
“..., a clinical phase 2b trial of Sanofi Pasteur's CYD tetravalent dengue vaccine revealed...”

Get access
Get access

Article in Journal/Newspaper